Guardant Complete
Backed by >80 clinical outcomes studies
and >400 peer-reviewed publications.
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer
Leighl NB, et al. Clin Cancer Res. 2019
Read more ›Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer
Page RD, et al. Clin Lung Cancer. 2022
Read more ›Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Aggarwal C, et al. JAMA Oncol. 2019
Read more ›Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program (SLLIP)
Palmero R, et al. J Thorac Onc. 2018
Read more ›Up-Front Cell-Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Cui W, et al. Eur J Cancer. 2022
Read more ›